The marijuana industry is extremely profitable, but finding a “safe” pot stock is easier said than done. Still, the allure of investing in marijuana is undeniable, as legal sales reached $6.7 billion in North America in 2016 and are expected to climb to $20 billion by 2020.
There’s no such thing as a completely safe investment, but we have uncovered one of the best marijuana stocks to own for risk-averse investors.
If you’ve owned it since 2013, you’ve already netted returns of 1,031%, and there could be more triple-digit gains ahead in the next 12 months...
The Price for This Safe Pot Stock Has Skyrocketed Over the Last Four Years
Most cannabis stocks are penny stocks that trade on over-the-counter (OTC) markets. OTC markets aren’t regulated like major indexes, and penny stock prices can be extremely volatile. For example, one of the marijuana penny stocks we’ve followed, MassRoots Inc. (OTCMKTS: MSRT) has traded between $0.38 per share and $1.18 per share in the last 52 weeks.
But that’s not the pot stock we’re recommending today...
Eventually, stocks like MassRoots could skyrocket as more states legalize medical marijuana. Wall Street will view buying cannabis stocks as less taboo, and cannabis companies will be able to get loans from banks and more easily buy real estate for their operations.
This will help marijuana companies meet the requirements to trade on the New York Stock Exchange (NYSE) and the Nasdaq.
Until then, these pot penny stocks like MassRoots will remain very speculative investments. In the meantime, we’re providing an investment for risk-averse investors in the legal cannabis market - one that has already climbed 1,031% since 2013.
If you missed out on those gains, that’s okay.
Over the next 12 months, one brokerage firm expects this company’s stock price to climb 103.28%.
This Is Creating Billionaires: This technology is projected to grow 63,000% and create $7 trillion in new wealth. Will you be able to capitalize on these windfall profits? Read more…
But to make that kind of profit, the best time to invest is now...
The “Safe” Pot Stock that Could Net Triple-Digit Gains in the Next 12 Months
[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]
GW Pharmaceuticals Plc. (Nasdaq ADR: GWPH) is a biopharmaceutical company that discovers, develops, and commercializes cannabinoid prescription medicines.
Since May 10, 2013, the GWPH stock price has climbed 1,033%.
And there are even more gains ahead in the next year as the company receives approval to launch cannabis-based medicine.
One of its products, Sativex, is an oromucosal spray that’s a formulated extract of the cannabis sativa plant. It’s administered as an oral spray and is used to treat patients with MS spasticity, which causes muscles to tighten and stiffen and can impact movements and speech.
According to GW’s website, the biopharmaceutical firm is commercializing Sativex for MS in 16 countries outside of the United States.
Which States Will Legalize Marijuana Next?
Even though it may be some time before Sativex is approved in America, GW is getting closer to releasing a cannabis-based drug stateside.
The company's cannabis-based drug that could be approved by the FDA is called Epidiolex.
Right now, Epidiolex is being tested for treating patients with childhood epilepsy and Dravet syndrome, a rare genetic epileptic dysfunction. It’s currently in phase 3 trials, in which the efficacy and side effects are monitored before a drug is approved, for Dravet Syndrome and Lennox-Gastaut Syndrome.
But eventually, Money Morning Director of Technology & Venture Capital Research Michael A. Robinson believes this will have a much wider range of uses as pain management.
"Children won't end up being Epidiolex's only focus. After all, chronic pain affects everyone, especially seniors – the drug industry's most important market," Robinson said.
Over the next 12 months, Cantor Fitzgerald projects the GWPH stock price will climb to $208 per share, according to FactSet. That's a gain of 103.28% from the Aug. 14 closing price of $102.32.
"We're at the beginning of a sea of change in how we treat chronic pain, shifting from opioid-based medications to cannabis-based ones. And with the first-mover advantage, we're in the perfect spot to profit," Robinson said.
“Chemotherapy Will Become Obsolete”: The FDA has approved a new medical device. It’s spreading rapidly to hospitals not only in all 50 states, but also to every country in Europe. It’s revolutionizing the treatment of nearly every form of cancer, which is why analysts project its sales to spike 63,000% and create $7 trillion in new wealth. Read more...